



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Junyan Wu,
✉ wujunyan@mail.sysu.edu.cn
Herui Yao,
✉ yaoherui@mail.sysu.edu.cn

RECEIVED 20 March 2024
ACCEPTED 08 April 2024
PUBLISHED 17 April 2024

CITATION
Lv X, Wu J, Yao H, Ye S and Zhang N (2024),
Corrigendum: Effect of itraconazole on the
safety and pharmacokinetics of
antitumor SHR6390.
Front. Drug Discov. 4:1397200.
doi: 10.3389/fddsv.2024.1397200

COPYRIGHT
© 2024 Lv, Wu, Yao, Ye and Zhang. This is an
open-access article distributed under the terms
of the [Creative Commons Attribution License
\(CC BY\)](#). The use, distribution or reproduction in
other forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in this
journal is cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Corrigendum: Effect of itraconazole on the safety and pharmacokinetics of antitumor SHR6390

Xiaozhi Lv, Junyan Wu*, Herui Yao*, Suiwen Ye and Nan Zhang

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

KEYWORDS

SHR6390, itraconazole, pharmacokinetic, safety, drug-drug interaction, healthy subjects

A Corrigendum on Effect of itraconazole on the safety and pharmacokinetics of antitumor SHR6390

by Wu J, Yao H, Lv X, Ye S and Zhang N (2022). *Front. Drug. Discov.* 2:963045. doi: [10.3389/fddsv.2022.963045](#)

In the published article, there was an error in the **Author list**, and author Xiaozhi Lv was erroneously listed as the third author, not the first. The corrected **Author list** appears below. “Xiaozhi Lv, Junyan Wu*, Herui Yao*, Suiwen Ye, Nan Zhang”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

In the published article, there was an error in the **Funding statement**. It was erroneously left out. The correct **Funding statement** appears below.

Funding

The authors declare that financial support was received for the research, authorship, and/or publication of this article. Funding went to principal investigator JW for the name of the clinical trial sponsor—itraconazole against SHR6390 in healthy subjects trial. This study was funded by Jiangsu Hengrui Pharmaceutical Co., Ltd. The involvement of funder in the study is as follows: the funders only participated in the design of national clinical trials, and the subsequent data collection, analysis and interpretation were all completed by the researchers of our center. The funders did not participate in the writing of this paper or the decision of whether to publish it.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.